“…The chemoenzymatic approach has been successfully employed in the synthesis of sLe x , but it has been limited by the cost, scalability, and variability. , Thus, many efforts have been devoted to the chemical synthetic approach , and led to synthetic glycomimetic selectin antagonists, such as Rivipansel (GMI-1070). However, compared to designing moieties with sulfate groups in inhibitors to mimic the sulfated amino acids in glycopeptides, the structural complexity underlying the stereospecific glycosidic linkages among monosaccharides requires more sophisticated strategies for placements of protecting groups and deprotecting processes, which extensively complicate the chemical synthetic approaches and reduce the yield of the final product. Therefore, replacing nonbinding-critical residues with synthetic accessible ones has great potential in simplifying the synthetic process for selectin inhibitors .…”